Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sonoma Pharmaceuticals (SNOA) Equity Ratio (2016 - 2025)

Sonoma Pharmaceuticals has reported Equity Ratio over the past 15 years, most recently at 0.25 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 29.29% year-over-year to 0.25; the TTM value through Dec 2025 reached 0.25, down 29.29%, while the annual FY2025 figure was 0.32, 22.63% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.25 at Sonoma Pharmaceuticals, down from 0.27 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.58 in Q3 2021 and troughed at 0.25 in Q4 2025.
  • A 5-year average of 0.41 and a median of 0.41 in 2022 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: plummeted 44.51% in 2021 and later skyrocketed 41.75% in 2022.
  • Year by year, Equity Ratio stood at 0.58 in 2021, then plummeted by 30.86% to 0.4 in 2022, then rose by 14.7% to 0.46 in 2023, then decreased by 22.17% to 0.36 in 2024, then dropped by 29.29% to 0.25 in 2025.
  • Business Quant data shows Equity Ratio for SNOA at 0.25 in Q4 2025, 0.27 in Q3 2025, and 0.28 in Q2 2025.